Free Trial
NASDAQ:TELO

Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Telomir Pharmaceuticals logo
$1.45 -0.05 (-3.33%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.46 +0.01 (+0.69%)
As of 08/22/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Telomir Pharmaceuticals Stock (NASDAQ:TELO)

Key Stats

Today's Range
$1.45
$1.51
50-Day Range
$1.13
$2.29
52-Week Range
$1.12
$8.40
Volume
169,180 shs
Average Volume
441,320 shs
Market Capitalization
$46.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Strong Buy

Company Overview

Telomir Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

TELO MarketRank™: 

Telomir Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat, and ranked 498th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Telomir Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Telomir Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Telomir Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Telomir Pharmaceuticals are expected to grow in the coming year, from ($0.40) to ($0.36) per share.

  • Price to Book Value per Share Ratio

    Telomir Pharmaceuticals has a P/B Ratio of 145.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Telomir Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.22% of the float of Telomir Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Telomir Pharmaceuticals has recently increased by 19.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Telomir Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Telomir Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.22% of the float of Telomir Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Telomir Pharmaceuticals has recently increased by 19.55%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 2 people have searched for TELO on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Telomir Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive TELO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TELO Stock News Headlines

TELO Makes Progress Toward Human Trials
Telomir Flat on Trial Data Release
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
TELO Announces Another Important Breakthrough
See More Headlines

TELO Stock Analysis - Frequently Asked Questions

Telomir Pharmaceuticals' stock was trading at $4.12 at the beginning of the year. Since then, TELO stock has decreased by 64.8% and is now trading at $1.45.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.09.

Telomir Pharmaceuticals (TELO) raised $7 million in an IPO on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments acted as the underwriter for the IPO.

Top institutional investors of Telomir Pharmaceuticals include Geode Capital Management LLC (0.66%), Marshall Wace LLP (0.25%), Y Intercept Hong Kong Ltd (0.22%) and Jane Street Group LLC (0.17%).

Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/14/2025
Today
8/23/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TELO
Previous Symbol
NASDAQ:TELO
CIK
1971532
Fax
N/A
Employees
1
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$15.00
Potential Upside/Downside
+934.5%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.53 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-4,595.08%
Return on Assets
-1,750.91%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.39
Quick Ratio
0.75

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
145.00

Miscellaneous

Outstanding Shares
32,281,000
Free Float
N/A
Market Cap
$46.81 million
Optionable
N/A
Beta
-0.67
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:TELO) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners